Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : RETA save search
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.1%
H: 5.34%
C: 0.82%
skyclarys approval pharmaceuticals commercial
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.5%
H: 0.81%
C: -3.62%
skyclarys fda approval pharmaceuticals
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.49%
H: 25.61%
C: 0.55%
fda pharmaceuticals drug approval friedreich’s ataxia
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.63%
H: 1.09%
C: -2.15%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 0.24%
H: 29.56%
C: 14.4%
treatment approval berubicin switzerland potential glioblastoma
CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2021-12-02 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.27%
H: 3.46%
C: -5.38%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 10.38%
H: 0.0%
C: -8.55%
treatment approval berubicin potential switzerland glioblastoma
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.